Adesis Announces Joanne Johnson as Vice President of Business Development

January 4, 2018

NEW CASTLE, Del.–(BUSINESS WIRE)–$OLED #CRO—Adesis,
Inc., a wholly-owned subsidiary of Universal
Display Corporation (Nasdaq:OLED), today announced that Joanne
Johnson, Ph.D. has been appointed Vice President of Business Development.

“I am delighted to welcome Joanne to the rapidly growing team at
Adesis,” said Andrew Cottone, Ph.D., President of Adesis, Inc. “Joanne
brings a wealth of international experience across various aspects of
the pharmaceutical and biotechnology business arenas. With her deep
technical, marketing and leadership expertise, Joanne will help enhance
our current collaborative relationships, develop new business
opportunities, and expand our partnership engagements. I am confident
that she will be a valuable asset in fostering our best-in-class
customer management and fueling revenue and business growth for the
Company.”

Prior to joining Adesis, Dr. Johnson was Vice President of Business
Development at Asymchem, Inc. During her 9-year tenure, she gained broad
and significant experience in building out global sales and support
teams, and managed significant revenue growth. Dr. Johnson also brings
technical and business-related experience from AMRI, Biofocus-DPI, the
Cancer Research Campaign (CRC) and Acambis. Dr. Johnson received her
Ph.D. from the University of Wales (UK) and her Bachelor's degree from
Durham University (UK). She completed postdoctoral research at both
Southampton and Cambridge.

“It is an incredibly exciting time to be joining Adesis,” said Joanne
Johnson. “As a leading organic synthesis CRO (contract research
organization) with a rich history of scientific excellence and the full
support of its parent company, Universal Display Corporation, Adesis is
uniquely positioned for its next phase of growth. To support its
bustling customer pipeline, the Company is expanding its portfolio of
discovery, development, and commercialization services as well as its
headcount and footprint. I am thrilled to be part of the world-class
team at Adesis and look forward to helping broaden its diverse customer
base, and grow through strategic partnerships.”

About Adesis, Inc.

As a wholly-owned subsidiary of Universal
Display Corporation, Adesis, Inc. is a contract research
organization (CRO) supporting the pharma, biotech, catalysis and a
number of other industries. The CRO specializes in organic and
organometallic synthesis, in milligrams to multi-kilogram quantities.
Adesis has a business model of providing clients with organic chemistry
services in three areas: early stage research, scale up and development,
and specialty manufacturing. With over 20 years of success and
approximately 60 chemists with extensive industry and professional
experience, Adesis supports companies in various industries with small
molecule organic chemistry expertise. Adesis provides a range of
services that can supplement research and development efforts. It can
also act as a specialty manufacturer to reinforce supply chains. To
learn more about Adesis, please visit http://adesisinc.com/.

About Universal Display Corporation

Universal Display Corporation (Nasdaq: OLED) is a leader in developing
and delivering state-of-the-art, organic light emitting diode (OLED)
technologies, materials and services to the display and lighting
industries. To learn more about Universal Display Corporation, please
visit http://www.oled.com.

All statements in this document that are not historical, such as
those relating to the Company’s technologies and potential applications
of those technologies, the Company’s expected results and future
declaration of dividends, as well as the growth of the OLED and CRO
market and the Company’s opportunities in that market, are
forward-looking financial statements within the meaning of the Private
Securities Litigation Reform Act of 1995. You are cautioned not to place
undue reliance on any forward-looking statements in this document, as
they reflect the Company’s current views with respect to future events
and are subject to risks and uncertainties that could cause actual
results to differ materially from those contemplated. These risks and
uncertainties are discussed in greater detail in Universal Display
Corporation’s periodic reports on Form 10-K and Form 10-Q filed with the
Securities and Exchange Commission, including, in particular, the
section entitled “Risk Factors” in Universal Display Corporation’s
annual report on Form 10-K for the year ended December 31, 2016.
Universal Display Corporation disclaims any obligation to update any
forward-looking statement contained in this document.